Regeneron Pharmaceuticals Inc
Biotechnology
Regeneron Pharmaceuticals Inc (REGN) Stock News
The latest REGN headlines and market coverage — 8 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals over allegations that the company made false and misleading statements regarding a Phase 3 clinical trial of Fianlimab for melanoma treatment. The trial failed to reach statistical significance on its primary endpoint, causing an $11 billion market cap loss. Investors claim Regeneron concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The lead plaintiff deadline is September 14, 2026.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.
- GlobeNewswire Inc.·
REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false and misleading statements about its Phase 3 clinical trial of Fianlimab for melanoma treatment. The company reportedly failed to disclose that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. After initially expressing confidence in the trial, Regeneron altered the trial protocol in November 2025 without timely disclosure and ultimately announced on May 15, 2026 that the trial failed to reach statistical significance, resulting in an $11 billion market cap loss.
- GlobeNewswire Inc.·
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is seeking investors to join a class action lawsuit against Regeneron Pharmaceuticals for securities fraud. The company allegedly made false and misleading statements about its Phase III Fianlimab-Libtayo study, claiming it was likely to succeed when it actually failed to demonstrate clinical differentiation from competing therapies. Investors who purchased securities between August 1, 2025 and May 15, 2026 are encouraged to participate before the September 14, 2026 deadline.
- GlobeNewswire Inc.·
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure
Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made false statements about trial progress while concealing that preliminary statistical assumptions were flawed and the treatment showed no meaningful differentiation over standard therapies. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.
- GlobeNewswire Inc.·
$REGN Securities: Suffer Losses on Your Regeneron Investment? BFA Law Reminds Investors of the Securities Fraud Lawsuit to Recover Losses
A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly misleading investors about the success of its Phase III Fianlimab-Libtayo clinical trial. The stock dropped 6.2% on April 29, 2026, and 9.8% on May 15, 2026, after the company announced the study failed to achieve statistical significance. Investors have until September 14, 2026, to request lead plaintiff status.
- GlobeNewswire Inc.·
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure
Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026, with a lead plaintiff deadline of September 14, 2026.
- GlobeNewswire Inc.·
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure - HBSS
Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance on May 15, 2026, resulting in an $11 billion market cap loss. The lawsuit covers investors who purchased shares between August 1, 2025 and May 15, 2026.